Juan G Ripoll, Sidna M Tulledge-Scheitel, Anthony A Stephenson, Shane Ford, Marsha L Pike, Ellen K Gorman, Sara N Hanson, Justin E Juskewitch, Alex J Miller, Solomiia Zaremba, Erik A Ovrom, Raymund R Razonable, Ravindra Ganesh, Ryan T Hurt, Erin N Fischer, Amber N Derr, Michele R Eberle, Jennifer J Larsen, Christina M Carney, Elitza S Theel, Sameer A Parikh, Neil E Kay, Michael J Joyner, Jonathon W Senefeld
Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients with immunosuppression have poor immunogenic responses to COVID-19 vaccines and remain at high risk of infection with SARS-CoV-2 and hospitalization. In addition, monoclonal antibody therapy is limited by the emergence of novel SARS-CoV-2 variants that have serially escaped neutralization. In this context, there is interest in understanding the clinical benefit associated with COVID-19 convalescent plasma collected from persons who have been both naturally infected with SARS-CoV-2 and vaccinated against SARS-CoV-2 ("vax-plasma")...
April 11, 2024: MBio